<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395108</url>
  </required_header>
  <id_info>
    <org_study_id>TG-873870-C-1</org_study_id>
    <nct_id>NCT01395108</nct_id>
  </id_info>
  <brief_title>Clinical Study on Oral Nemonoxacin Malate Capsules</brief_title>
  <official_title>Phase I Clinical Study on Oral Nemonoxacin Malate Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of nemonoxacin in
      healthy Chinese volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single dose study: evaluate safety and tolerability of oral nemonoxacin 125 mg, 250mg, 500mg,
      750mg, and 1000mg.

      Multiple dose study: evaluate PK profile of oral doses of 500mg or 750mg nemo after
      consecutive 10 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated single oral dose of nemonoxacin in healthy Chinese volunteers</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of single oral dose of nemonoxacin in healthy Chinese volunteers</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of repeated oral doses of nemonoxacin in healthy Chinese volunteers</measure>
    <time_frame>17 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 125mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 125mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 250mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 250mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 500mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 750mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 750mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 1000mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 1000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemonoxacin</intervention_name>
    <description>oral once daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Nemonoxacin 125mg</arm_group_label>
    <arm_group_label>Nemonoxacin 250mg</arm_group_label>
    <arm_group_label>Nemonoxacin 500mg</arm_group_label>
    <arm_group_label>Nemonoxacin 750mg</arm_group_label>
    <arm_group_label>Nemonoxacin 1000mg</arm_group_label>
    <other_name>TG-873870</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females, aged between 18 and 45 during screening

          -  Male volunteers who are capable of taking double-barrier contraception measures during
             the test (spermicide gel plus condom, for instance) until the end of the clinical
             study and do not cause their spouses to conceive within three months after the last
             administration of the medication; if the subjects are females, they shall not become
             pregnant during the test and within three months after the study

          -  No use of tobacco or nicotine product within 3 months prior to this study

          -  BMI 19-25

          -  Willing to abstain from coffee and any caffeine drink during the study

          -  Voluntarily sign the informed consent

        Exclusion Criteria:

          -  History of diabetes, or cardiovascular, hepatic or renal disease

          -  Active digestive disease (e.g. diarrhea)

          -  Central nervous disease or psychiatric disorders

          -  Had surgery or trauma within 6 months prior to this study

          -  Alcohol or drug abuse

          -  HIV, HBV or HCV positive

          -  Used any prescribed drug (including traditional chinese medicine) within 14 days prior
             to the study

          -  Donated 400ml of blood or plasma within 3 months prior to this study

          -  Have an abnormal laboratory examination value that exceeds the normal range by 10%

          -  Drug allergies

          -  Have cardiac disorders or have a family history of cardiac disorders

          -  Have abnormal 12-lead ECG during screening

          -  Pregnant or lactating

          -  Participated in any study within 3 months prior to this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingyuan Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital, Fundan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Antibiotics, Huashan Hospital, Fundan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <last_update_submitted>July 13, 2011</last_update_submitted>
  <last_update_submitted_qc>July 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yingyuan Zhang</name_title>
    <organization>Institute of Antibiotics, Huashan Hospital, Fundan University</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

